GSK and Theravance announce regulatory submission for UMEC/VI (LAMA/LABA) in the US
18 December 2012 | By GlaxoSmithKline
ANORO ELLIPTA™ proposed proprietary name for UMEC/VI...
List view / Grid view
18 December 2012 | By GlaxoSmithKline
ANORO ELLIPTA™ proposed proprietary name for UMEC/VI...
17 December 2012 | By GlaxoSmithKline
“These regulatory submissions are an important step for ViiV Healthcare..."
14 December 2012 | By GlaxoSmithKline
The U.S. FDA has approved raxibacumab...
10 December 2012 | By GlaxoSmithKline
Partnership aims to create sustainable and scalable model to be replicated across Africa...
28 November 2012 | By GlaxoSmithKline
GSK welcomes the publication of the third Access to Medicines (ATM) Index...
26 November 2012 | By GlaxoSmithKline
GSK and GSK Nigeria have reached agreement...
20 November 2012 | By GlaxoSmithKline
GSK will be a headline partner at the Coronation Festival...
19 November 2012 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. FDA has approved PROMACTA for the treatment of thrombocytopenia...
16 November 2012 | By GlaxoSmithKline
Results from the first randomised controlled European clinical trial...
14 November 2012 | By GlaxoSmithKline
“GSK has been collaborating with the U.S. Department of Health and Human Services..."
13 November 2012 | By GlaxoSmithKline
24-week data from VIKING-3 Phase III study...
9 November 2012 | By GlaxoSmithKline
Results from ongoing Phase III clinical trial announced...
2 November 2012 | By GlaxoSmithKline
Anthrax has been identified as a serious potential threat...
31 October 2012 | By GlaxoSmithKline
“GSK fully supports the commitment made by BMJ to drive greater transparency of clinical trial data..."
30 October 2012 | By GlaxoSmithKline
GlaxoSmithKline announced the start of a Phase III programme...